AG0036OD

69655-05-6 | 9-[(2R,5S)-5-(hydroxymethyl)oxolan-2-yl]-6,9-dihydro-1H-purin-6-one

AG0036OD

SDS

COA

Price

$0.00

Add to Cart

Buy Now

WARNING This product is not for human or veterinary use.

CAS Number	69655-05-6
Catalog Number	AG0036OD(AGN-PC-0OGSCX)
Chemical Name	9-[(2R,5S)-5-(hydroxymethyl)oxolan-2-yl]-6,9-dihydro-1H-purin-6-one
EC Number	614-994-4
IUPAC Name	9-[(2R,5S)-5-(hydroxymethyl)oxolan-2-yl]-1H-purin-6-one
InChI	InChI=1S/C10H12N4O3/c15-3-6-1-2-7(17-6)14-5-13-8-9(14)11-4-12-10(8)16/h4-7,15H,1-3H2,(H,11,12,16)/t6-,7+/m0/s1
InChI Key	BXZVVICBKDXVGW-NKWVEPMBSA-N
MDL Number	MFCD00077728
Molecular Formula	C10H12N4O3
Molecular Weight	236.2273
SMILES	OC[C@@H]1CC[C@H](N2C=NC3=C2NC=NC3=O)O1
UNII	K3GDH6OH08
Synonyms	2',3' Dideoxyinosine, 2',3'-Dideoxyinosine, ddI (Antiviral), Didanosine, Dideoxyinosine, NSC 612049, NSC-612049, NSC612049, Videx, didanosine, 2',3'-Dideoxyinosine, 69655-05-6, DIDEOXYINOSINE, Videx, Videx EC, Inosine, 2',3'-dideoxy-, ddIno, Didanosina, Didanosinum, DDI, BMY-40900, UNII-K3GDH6OH08, K3GDH6OH08, Didanosinum [INN-Latin], Didanosina [INN-Spanish], CHEBI:490877, 9-(2,3-Dideoxy-beta-D-ribofuranosyl)-6-oxopurine, 9-[(2R,5S)-5-(hydroxymethyl)tetrahydrofuran-2-yl]-1,9-dihydro-6H-purin-6-one, NSC 612049, MFCD00077728, 9-[(2R,5R)-5-(HYDROXYMETHYL)TETRAHYDROFURAN-2-YL]-1,9-DIHYDRO-6H-PURIN-6-ONE, NCGC00090691-03, NCGC00159514-02, DRG-0016, BMY 40900, DSSTox_CID_2927, DSSTox_RID_76791, DSSTox_GSID_22927, CCRIS 805, 2',3'-Dideoxyinosine (ddI), HSDB 6548, 9-((2R,5S)-5-(hydroxymethyl)tetrahydrofuran-2-yl)-9H-purin-6-ol, 9-[(2R,5S)-5-(hydroxymethyl)tetrahydrofuran-2-yl]-3H-purin-6-one, Hypoxanthine ddN, NSC612049, 9-((2R,5S)-5-(hydroxymethyl)tetrahydrofuran-2-yl)-3,9-dihydro-6H-purin-6-one, 9-[(2R,5S)-5-(HYDROXYMETHYL)OXOLAN-2-YL]-6,9-DIHYDRO-1H-PURIN-6-ONE, 9-[(2R,5S)-5-(HYDROXYMETHYL)OXOLAN-2-YL]-6,9-DIHYDRO-3H-PURIN-6-ONE, BRN 3619529, 2DI, D2I, SMR000058576, Videx(TM), 2,3-dideoxyinosine, Intron A & Videx, CAS-69655-05-6, Videx (TN), PC-SOD+ddI, Dideoxyinosine (DDI), LOA & ddI, ddI + d4T combination, ddI & GM-CSF, SR-05000001487, DDI and rIFN.alpha.2, ddI & sCD4(rsCD4), 2'3'-DIDEOXYINOSINE, Didanosine (JAN/USAN/INN), 9-[(2R,5S)-5-(hydroxymethyl)tetrahydrofuran-2-yl]-1H-purin-6-one, DS-4152 & ddI, Didanosine(Videx), Didanosine,(S), Videx EC;Videx, 3'-dideoxyinosine, Didanosine [USAN:USP:INN:BAN], Didanosine (DDI), Didanosine (Videx), Didanosine and Interferon-.alpha.-2, Videx EC(TM)(slow-release capsules), KS-1049, 2',3'-didesoxyinosin, 2',3'-Dideoxyinosine (AIDS Initiative), ddI & IFN-.alpha., 2', 3'-dideoxyinosine, AC1L19ET, SCHEMBL3363, CHEMBL1460, 9-(2,3-Dideoxy-beta-D-ribofuranosyl)hypoxanthine, Listera ovata agglutinin & 2',3'-Dideoxyinosine, MLS000759469, MLS001055350, MLS001424118, MLS002154216, MLS006011561, 3'-Azido-3'-deoxythymidine + 2',3'-Dideoxyinosine, GTPL4833, INO001, DTXSID6022927, KS-00000FVB, 2',3'-Dideoxyinosine & sCD4(soluble recombinant protein), BXZVVICBKDXVGW-NKWVEPMBSA-N, 9-[(2R,5S)-5-(hydroxymethyl)oxolan-2-yl]-3H-purin-6-one, HMS2051J11, HMS2089N20, HMS2095O08, HMS2232P22, HMS3712O08, HY-B0249, Tox21_111732, Tox21_202333, Tox21_300575, ANW-35738, BDBM50404252, Sulfated polysaccharide-peptidoglycan DS-4152 & 2',3'-Dideoxyinosine, ZINC13597823, 2',3'-Dideoxyinosine & Granulocyte-macrophage colony-stimulating factor, 2',3'-DIDEOXYINOSINE; Didanosine, 9-((2R,5S)-5-(hydroxymethyl)-tetrahydrofuran-2-yl)-1H-purin-6(9H)-one, 9-((2R,5S)-5-Hydroxymethyl-tetrahydro-furan-2-yl)-1,9-dihydro-purin-6-one, AKOS015833088, AKOS015901454, AKOS015963259, AKOS026750545, Tox21_111732_1, AB02981, CCG-100947, CCG-220153, CS-2229, DB00900, MCULE-2844514954, NC00197, RTR-030612, SRI-7013-04, SRI-7013-05, SRI-7013_07, NCGC00090691-01, NCGC00090691-02, NCGC00159514-03, NCGC00159514-04, NCGC00164280-01, NCGC00188983-01, NCGC00254496-01, NCGC00259882-01, NCGC00390773-01, AC-12026, AJ-64234, AN-37869, BC203896, CJ-14439, CPD000058576, K166, SAM001246673, SC-58339, SMR004703324, 2',3'-Dideoxyinosine, >=98% (HPLC), AB0014064, AB0069772, AB2000230, DB-055315, TR-030612, 2',3'-Dideoxyinosine & Interferon-.alpha., D3066, FT-0082664, SW198619-2, 9-((2R,5S)-5-(hydroxymethyl)tetrahydrofuran, C06953, D00296, J10315, 655D056, J-700356, SR-05000001487-1, SR-05000001487-2, W-203551, Z1692482604, Didanosine, European Pharmacopoeia (EP) Reference Standard, 9-[(2R,5S)-5-(hydroxymethyl)oxolan-2-yl]-1H-purin-6-one, Didanosine, United States Pharmacopeia (USP) Reference Standard, Inosine, 2',3'-dideoxy- & Recombinant Interferon-.alpha.-2, Lecithinized superoxide dismutase & Inosine, 2',3'-dideoxy-, 2 inverted exclamation mark ,3 inverted exclamation mark -Dideoxyinosine, 9-((2R,5S)-5-(HYDROXYMETHYL)TETRAHYDROFURAN-2-YL)-1H-PURIN-6(9H)-ONE, Didanosine for system suitability, European Pharmacopoeia (EP) Reference Standard, Didanosine(DD), ddI (Antiviral), DdI & IFN-alpha, Videx EC (TN), 2',3' Dideoxyinosine, D06FDR, D0P6OM, Inosina, 2',3'-dideoxi-, Didanosine [USAN:BAN:INN], Didanosine [USAN:INN:BAN], C10H12N4O3, -2-yl)-1H-purin-6(9H)-one, NSC-612049, CID50599, C10-H12-N4-O3, CS-O-01310, 2',3'-Dideoxyinosine & Interferon-alpha, A8410, S1702, D016049, 2',3'-dideoxyinosine, DDI, NSC 612049, Didanosine, Inosine, 2',3'-dideoxy-& Recombinant Interferon-.alpha.-2, 2',3'-Dideoxyinosine, 98%, reverse transcriptase inhibitor - 100MG 100mg,

Complexity	348
Compound Is Canonicalized	Yes
Covalently-Bonded Unit Count	1
Defined Atom Stereocenter Count	2
Defined Bond Stereocenter Count	0
Exact Mass	236.091g/mol
Formal Charge	0
Heavy Atom Count	17
Hydrogen Bond Acceptor Count	5
Hydrogen Bond Donor Count	2
Isotope Atom Count	0
Molecular Weight	236.231g/mol
Monoisotopic Mass	236.091g/mol
Rotatable Bond Count	2
Topological Polar Surface Area	88.7A^2
Undefined Atom Stereocenter Count	0
Undefined Bond Stereocenter Count	0
XLogP3	-1.2

GHS Hazard and Precautionary Statements

Symbol:
Hazard Class
Hazard statements	H302-H315-H319-H335
Packing Group
Precautionary statements	P261-P305+P351+P338
UN Code

Certificate of Analysis

Lot Number